Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$221,000.

  • Adma Biologics' Change in Accured Expenses fell 15.71% to -$221,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 56.46%. This contributed to the annual value of -$1.1 million for FY2024, which is 115.19% down from last year.
  • As of Q3 2025, Adma Biologics' Change in Accured Expenses stood at -$221,000, which was up 92.12% from -$2.8 million recorded in Q2 2025.
  • Adma Biologics' Change in Accured Expenses' 5-year high stood at $6.9 million during Q4 2022, with a 5-year trough of -$6.0 million in Q2 2024.
  • For the 3-year period, Adma Biologics' Change in Accured Expenses averaged around $87,182, with its median value being -$191,000 (2024).
  • In the last 5 years, Adma Biologics' Change in Accured Expenses spiked by 1,840.40% in 2023 and then plummeted by 411.01% in 2025.
  • Adma Biologics' Change in Accured Expenses (Quarterly) stood at $2.8 million in 2021, then spiked by 143.96% to $6.9 million in 2022, then tumbled by 61.29% to $2.7 million in 2023, then soared by 59.52% to $4.2 million in 2024, then dropped by 15.71% to -$221,000 in 2025.
  • Its last three reported values are -$221,000 in Q3 2025, -$2.8 million for Q2 2025, and -$2.4 million during Q1 2025.